Health plans and payers have plenty of options for how to analyze the effectiveness of digital therapeutic tools, as there are several effective strategies, according to Soumya Vishwanath, PharmD, of Magellan Rx Management.
Health plans and payers have plenty of options for how to analyze the effectiveness of digital therapeutic tools as there are several effective strategies, according to Soumya Vishwanath, PharmD, senior manager of Formulary Management at Magellan Rx Management, at the Academy of Managed Care Pharmacy's annual meeting.
Transcript
What are some of the different strategies that health systems have implemented to assess the effectiveness of digital therapeutic tools?
Some of the strategies that some health plans and payers have implemented are creating an objective criteria on how to review digital therapeutics products based on priorities that are important to them. So, recognizing what's the scope that they want to evaluate; whether it's digital health, digital medicine, digital therapeutics, or a scope in a specific disease state. That's a great objective start to reviewing and evaluating these products and understanding whether it would serve their patient population and be appropriate for their formulary.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More